
Heliyon, Год журнала: 2024, Номер 10(23), С. e40812 - e40812
Опубликована: Ноя. 30, 2024
Язык: Английский
Heliyon, Год журнала: 2024, Номер 10(23), С. e40812 - e40812
Опубликована: Ноя. 30, 2024
Язык: Английский
Clinical Reviews in Allergy & Immunology, Год журнала: 2025, Номер 68(1)
Опубликована: Янв. 17, 2025
Язык: Английский
Процитировано
1International Immunopharmacology, Год журнала: 2025, Номер 147, С. 113984 - 113984
Опубликована: Янв. 5, 2025
Язык: Английский
Процитировано
0Frontiers in Pharmacology, Год журнала: 2025, Номер 15
Опубликована: Янв. 7, 2025
Atherosclerotic cardiovascular disease (ASCVD) causes significant morbidity and mortality globally. Most of the chemicals specifically target certain pathways minimally impact other diseases associated with ASCVD. Moreover, interactions these drugs can cause toxic reactions. Consequently, exploration multi-targeted safe medications for treating preventing ASCVD has become an increasingly popular trend. Gallic acid (GA), a natural secondary metabolite found in various fruits, plants, nuts, demonstrated potentials ASCVD, addition to its known antioxidant anti-inflammatory effects. It alleviates entire process atherosclerosis (AS) by reducing oxidative stress, improving endothelial dysfunction, inhibiting platelet activation aggregation. Additionally, GA treat ASCVD-related diseases, such as coronary heart (CHD) cerebral ischemia. However, pharmacological actions prevention treatment have not been comprehensively reviewed, which limits clinical development. This review primarily summarizes vitro vivo on related risk factors AS, it provides comprehensive overview toxicity, extraction, synthesis, pharmacokinetics, pharmaceutics GA,aimed enhance understanding applications further research
Язык: Английский
Процитировано
0Next research., Год журнала: 2025, Номер unknown, С. 100218 - 100218
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Critical Reviews in Oncology/Hematology, Год журнала: 2025, Номер unknown, С. 104674 - 104674
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Experimental Cell Research, Год журнала: 2025, Номер unknown, С. 114494 - 114494
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0APOPTOSIS, Год журнала: 2025, Номер unknown
Опубликована: Март 5, 2025
Язык: Английский
Процитировано
0Drug Resistance Updates, Год журнала: 2025, Номер 81, С. 101223 - 101223
Опубликована: Март 8, 2025
Taxanes are effective in several solid tumors. Paclitaxel, the main clinically available taxane, was approved early nineties, for treatment of ovarian cancer and later on, together with analogs docetaxel cabazitaxel, other malignancies. By interfering microtubule function impairing separation sister cells at mitosis, taxanes act as antimitotic agents, thereby counteracting high proliferation rate cells. The action goes beyond their because cellular targets, microtubules, participate multiple processes such intracellular transport cell shape maintenance. clinical efficacy is limited by development resistance mechanisms. Among these, extracellular vesicles have emerged new players. In addition, taxane metronomic schedules shows an impact on tumor microenvironment reflected antiangiogenic immunomodulatory effects, aspect growing interest considering inclusion regimens immunotherapeutics. Preclinical studies paved bases synergistic combinations both conventional targeted agents. A variety drug delivery strategies provided novel opportunities to increase activity. ability orchestrate different effects amenable modulation suggests options improve cures lethal
Язык: Английский
Процитировано
0Experimental and Molecular Pathology, Год журнала: 2025, Номер 142, С. 104963 - 104963
Опубликована: Март 27, 2025
Язык: Английский
Процитировано
0Molecular Neurobiology, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0